S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
NASDAQ:ONTX

Onconova Therapeutics - ONTX Stock Forecast, Price & News

$0.85
-0.01 (-1.16%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.83
$0.87
50-Day Range
$0.63
$0.90
52-Week Range
$0.62
$2.06
Volume
74,487 shs
Average Volume
72,791 shs
Market Capitalization
$17.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Onconova Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
957.6% Upside
$9.00 Price Target
Short Interest
Healthy
0.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Onconova Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.91) to ($0.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

322nd out of 1,054 stocks

Pharmaceutical Preparations Industry

149th out of 517 stocks


ONTX stock logo

About Onconova Therapeutics (NASDAQ:ONTX) Stock

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
ONTX.O - | Stock Price & Latest News | Reuters
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
ONTX Onconova Therapeutics, Inc.
See More Headlines
Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Company Calendar

Last Earnings
11/14/2022
Today
1/29/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONTX
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+722.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-16,160,000.00
Net Margins
-7,658.41%
Pretax Margin
-7,658.41%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$2.22 per share

Miscellaneous

Free Float
20,645,000
Market Cap
$17.79 million
Optionable
Not Optionable
Beta
1.50

Key Executives

  • Steven M. FruchtmanSteven M. Fruchtman
    President, Chief Executive Officer & Director
  • Mark P. Guerin
    Chief Operating & Financial Officer
  • Matthew Parris
    Vice President-Clinical Operations
  • Mark Stephen Gelder
    Chief Medical Officer
  • Adar Makovski Silverstein
    Senior Director & Head-Corporate Development













ONTX Stock - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings
or view top-rated stocks.

What is Onconova Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price targets for Onconova Therapeutics' stock. Their ONTX share price forecasts range from $7.00 to $11.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 957.6% from the stock's current price.
View analysts price targets for ONTX
or view top-rated stocks among Wall Street analysts.

How have ONTX shares performed in 2023?

Onconova Therapeutics' stock was trading at $0.6457 at the beginning of the year. Since then, ONTX shares have increased by 31.8% and is now trading at $0.8510.
View the best growth stocks for 2023 here
.

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our ONTX earnings forecast
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.06 million. Onconova Therapeutics had a negative net margin of 7,658.41% and a negative trailing twelve-month return on equity of 43.20%.

When did Onconova Therapeutics' stock split?

Shares of Onconova Therapeutics reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.85.

How much money does Onconova Therapeutics make?

Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $17.79 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-16,160,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681.

This page (NASDAQ:ONTX) was last updated on 1/29/2023 by MarketBeat.com Staff